IOM Report Urges FDA Shift from 510(k) Program | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –The Institute of Medicine today proposed that the US Food and Drug Administration effectively scrap its 35 year-old 510(k) medical devices clearance program in favor of a hybrid model that would mix pre-market and post-market review activities in order to better protect consumers and promote innovation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.